within Pharmacolibrary.Drugs.ATC.N;

model N06AB07
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.5,
    Cl             = 10 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 100 / 1000000,
    adminCount     = 1,
    Vd             = 0.15,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0005,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Alaproclate is a selective serotonin reuptake inhibitor (SSRI) that was primarily investigated as an antidepressant in the 1970s and 1980s. It is not currently approved for clinical use and is not used in medical practice today.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for adult population (sex and comorbidities unspecified), as no direct published sources reporting precise human pharmacokinetics were found.</p><h4>References</h4><ol><li><p>Teunissen, MW, et al., &amp; Breimer, DD (1984). Influence of alaproclate on antipyrine metabolite formation in man. <i>European journal of clinical pharmacology</i> 27(4) 447â€“452. DOI:<a href=&quot;https://doi.org/10.1007/BF00549593&quot;>10.1007/BF00549593</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/6519152/&quot;>https://pubmed.ncbi.nlm.nih.gov/6519152</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end N06AB07;
